116 related articles for article (PubMed ID: 36435059)
21. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
22. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD
Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
24. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
25. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
26. Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer.
Gibson JT; Orlandella RM; Turbitt WJ; Behring M; Manne U; Sorge RE; Norian LA
Front Immunol; 2020; 11():590794. PubMed ID: 33123173
[TBL] [Abstract][Full Text] [Related]
27. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.
Mehdizadeh R; Shariatpanahi SP; Goliaei B; Rüegg C
Sci Rep; 2023 Apr; 13(1):5875. PubMed ID: 37041172
[TBL] [Abstract][Full Text] [Related]
28. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.
Su MT; Kumata S; Endo S; Okada Y; Takai T
Oncoimmunology; 2022; 11(1):2060907. PubMed ID: 35402083
[TBL] [Abstract][Full Text] [Related]
29. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden.
Rashid OM; Nagahashi M; Ramachandran S; Graham L; Yamada A; Spiegel S; Bear HD; Takabe K
Surgery; 2013 Jun; 153(6):771-8. PubMed ID: 23489938
[TBL] [Abstract][Full Text] [Related]
30. Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis.
Sevmis M; Yoyen-Ermis D; Aydin C; Bilgic E; Korkusuz P; Uner A; Hamaloglu E; Esendagli G; Karakoc D
Immunol Invest; 2017 Oct; 46(7):663-676. PubMed ID: 28872973
[TBL] [Abstract][Full Text] [Related]
31. Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer.
Zhang Y; Hughes KR; Raghani RM; Ma J; Orbach S; Jeruss JS; Shea LD
Biomaterials; 2021 Feb; 269():120666. PubMed ID: 33461057
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice.
Chandra D; Jahangir A; Quispe-Tintaya W; Einstein MH; Gravekamp C
Br J Cancer; 2013 Jun; 108(11):2281-90. PubMed ID: 23640395
[TBL] [Abstract][Full Text] [Related]
33. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
[TBL] [Abstract][Full Text] [Related]
34. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
35. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
36. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.
Oh K; Lee OY; Shon SY; Nam O; Ryu PM; Seo MW; Lee DS
Breast Cancer Res; 2013; 15(5):R79. PubMed ID: 24021059
[TBL] [Abstract][Full Text] [Related]
37. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
38. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
[TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of myeloid-derived suppressor cells in the tumor microenvironment by low-dose doxorubicin to improve immune efficacy in murine neuroblastoma.
Xu WL; Shi BJ; Li SL; Yu FX; Guo LN; Li M; Hu ZG; Li GX; Zhou H
Chin Med J (Engl); 2020 Dec; 134(3):334-343. PubMed ID: 33278092
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
